The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: MGC Pharmaceuticals loss widens, Codex eyes acquisitions

Fri, 29th Sep 2023 12:26

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Alpha Growth PLC - London-based financial advisory firm - Reports GBP323,588 pretax loss for first half of 2023, narrowed from GBP454,635 the prior year. Revenue increases 53% to GBP2.5 million from GBP1.6 million, with revenue from owned insurance companies up 52% to GBP2.2 million from GBP1.5 million. Operating expenses increase 87% to GBP1.5 million from GBP828,971. Company says loss reflects transition and integration costs associated with Alpha International Life Insurance Co, and these are now largely resolved. Expects cash flow to improve and does not expect a share placing to be necessary, except for strategic acquisition and growth purposes.

----------

MGC Pharmaceuticals Ltd - pharmaceutical company specialising in plant-derived medicines - Pretax loss for first half widens to AUD21.1 million, around GBP11.2 million, from AUD20.8 million the prior year. Revenue from contracts with customers falls 28% to AUD3.4 million from AUD4.7 million. Cost of sales fall 34% to AUD1.9 million, while administrative expenses increase 25% to AUD14.8 million. Company on Tuesday said it is at a "critical financial juncture" and has proposed a restructuring plan, including a share placement at an 80% discount to its average stock price in Sydney.

----------

Celsius Resources Ltd - West Perth, Australia-based explorer focused on copper-gold resources in the Philippines - Pretax loss for year ended June 30 widened to AUD5.8 million from AUD3.9 million the year before. Cash and equivalents balance was AUD5.0 million at June 30, up from AUD1.3 million at the same time one year prior. Executive Chair Julito Sarmiento says financial 2023 was "challenging" for Celsius, which "underwent major changes at the board level to ensure [its] sustainability," and notes the death of Chair Martin Buckingham in November 2022.

----------

Hiro Metaverse Acquisitions I SA - special purpose acquisition company sponsored by Hiro Sponsor - Reports pretax loss of GBP11.1 million in first half of 2023, compared with GBP5.3 million loss for the whole of 2022. Cash and equivalents at June 30 total GBP847,422, down from GBP1.2 million at December 31.

----------

Cadence Minerals PLC - London-based investor backing mineral resource assets - Pretax loss for first half of 2023 is GBP2.0 million, narrowed from GBP5.0 million. Operating loss narrows to GBP2.3 million from GBP5.1 million. Cash and equivalents balance at June 30 was GBP577,000, down from GBP2.0 million at the same time in 2022. Chief Executive Officer Kiran Morzaria says Cadence faced "unprecedented geopolitical challenges and challenging global markets" during the period. Adds that developments at flagship Amapa project and investments in portfolio companies hopefully will be affected during the second half.

----------

Codex Acquisitions PLC - special acquisition company - Pretax loss for the first half of 2023 is GBP29,352, compared with GBP206,444 for the period from October 11, 2021 to June 30, 2022. Cash position was GBP604,000 at June 30, down from GBP654,000 at the same time in 2022. Says its near-term goal is still undertake one or more acquisitions in the clean and renewable energy sector, and is currently focused on evaluating opportunities.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.